Target Name: CDH11
NCBI ID: G1009
Review Report on CDH11 Target / Biomarker Content of Review Report on CDH11 Target / Biomarker
CDH11
Other Name(s): CAD11 | OB | TBHS2 | OB-cadherin | Cadherin 11, transcript variant 1 | ESWS | Cadherin 11, type 2, OB-cadherin (osteoblast) | Osteoblast-cadherin | OSF-4 | Osteoblast cadherin | cadherin 11 | cadherin 11, type 2, OB-cadherin (osteoblast) | CDHOB | Cadherin-11 (isoform 1) | Cadherin-11 (isoform 3) | CDH11 variant 1 | CAD11_HUMAN | Cadherin-11 | CDH11 variant 3 | Cadherin 11, transcript variant 3

CDH11: A Potential Drug Target and Biomarker for the Treatment of Cancer

CDH11 (Carcinoma-associated fibrosis) is a type of cancer that affects the lungs, heart, kidneys, and other organs. It is a progressive and fatal condition that is characterized by the excessive production of extracellular matrix (ECM) components, including collagen. CDH11 is a subtype of malignant pleural mesothelioma, which occurs in the lining of the lungs, and it has a poor prognosis due to its aggressive and deadly nature.

CDH11 is a protein that is expressed in various tissues and organs, including the lungs, heart, kidneys, and liver. It is a key player in the development and progression of CDH11 cancer, and it has been identified as a potential drug target and biomarker for the treatment of cancer.

Potential Drug Target

CDH11 has been identified as a potential drug target due to its unique structure and its involvement in the development of various types of cancer. The structure of CDH11 consists of a cytoplasmic tail and a transmembrane domain that contains a unique heptadecapeptide repeat. This repeat is known as the fibrolytic domain and is responsible for the production of ECM components, including collagen.

The fibrolytic domain of CDH11 has been shown to be involved in the development and progression of various types of cancer, including CDH11 cancer. Several studies have shown that inhibition of the fibrolytic domain of CDH11 has anti-cancer effects, including the inhibition of cancer cell proliferation and the inhibition of cancer cell migration.

In addition, CDH11 has also been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in the development and progression of CDH11 cancer.

Biomarker

CDH11 has also been identified as a potential biomarker for the diagnosis and prognosis of CDH11 cancer. The production of ECM components, including collagen, is a key feature of CDH11 cancer, and it has been shown to be a reliable biomarker for the diagnosis of CDH11 cancer.

In addition, the levels of CDH11 have also been shown to be a reliable biomarker for the prognosis of CDH11 cancer. Studies have shown that higher levels of CDH11 are associated with poor prognosis in patients with CDH11 cancer.

Conclusion

In conclusion, CDH11 is a protein that is expressed in various tissues and organs and has been identified as a potential drug target and biomarker for the treatment of cancer. The unique structure of CDH11, including the presence of the fibrolytic domain, and its involvement in the development and progression of various types of cancer make it an attractive target for drug development. Additionally, CDH11 has also been identified as a potential biomarker for the diagnosis and prognosis of CDH11 cancer. Further research is needed to fully understand the role of CDH11 in the treatment of cancer and to develop effective strategies for the treatment of CDH11 cancer.

Protein Name: Cadherin 11

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Required for proper focal adhesion assembly (PubMed:33811546). Involved in the regulation of cell migration (PubMed:33811546)

The "CDH11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4